Advances in the Management of Pediatric Sarcomas

Fiorela N Hernandez Tejada1, Alejandro Zamudio1, Mario L Marques-Piubelli2

  • 1Division of Pediatrics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.

Current Oncology Reports
|November 16, 2020
PubMed
Abstract

Insights

Pediatric sarcoma patients with metastatic or recurrent disease have a poor prognosis. Advances in novel therapies and clinical trials offer hope for improved outcomes in refractory pediatric sarcomas.

Area of Science:

  • Pediatric Oncology
  • Sarcoma Research
  • Clinical Trials

Background:

  • Metastatic and recurrent pediatric sarcomas have a dismal prognosis.
  • Decades of research have yielded limited improvement in outcomes for these rare cancers.
  • A deeper understanding of sarcoma biology is crucial for developing effective treatments.

Purpose of the Study:

  • To review recent advances in managing metastatic and relapsed pediatric sarcoma.
  • To highlight current and future clinical trials for pediatric sarcoma.
  • To discuss challenges and promising strategies in novel sarcoma therapy.

Main Methods:

  • Literature review of recent advancements in pediatric sarcoma management.
  • Analysis of ongoing and upcoming clinical trials.
  • Discussion of therapeutic targets and challenges.

Main Results:

  • Novel therapies for refractory pediatric sarcomas are under active investigation.
  • Despite challenges like target selection and toxicity, promising strategies are emerging.
  • Research focuses on understanding tumor biology and identifying new molecular targets.

Conclusions:

  • Significant challenges persist in treating refractory pediatric sarcomas.
  • Ongoing research and clinical trials are essential for improving patient outcomes.
  • New therapeutic strategies hold promise for the future of pediatric sarcoma treatment.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.3K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
97